AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy

Rita De Santis, Barbara Leoni, Antonio Rosi, Claudio Albertoni, Guido Forni, Rodica Cojoca, Manuela Iezzi, Piero Musiani, Giovanni Paganelli, Marco Chinol, Paolo Carminati

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Avidin is widely used in vitro for its capacity to bind biotin. However, avidińs in vivo use is limited by its short residence in blood and tissues. An avidin variant, named AvidinOX,™ has been recently described. This product is obtained by 4-hydroxyazobenzene-2-carboxylic acid-assisted sodium periodate oxidation of avidin. This method generates aldehyde groups from avidin carbohydrates, sparing biotin-binding sites from inactivation. AvidinOX binds cellular and interstitial protein amino groups through Schiff's bases, resulting in a tissue half-life of 2 weeks, compared with 2 hours of native avidin. Binding of AvidinOX occurs in normal and neoplastic tissues. Data show that AvidinOX, administered intranipple in the breast of transgenic BALB/neuT mice, is highly efficient for capturing 90Y-biotinDOTA, intravenously injected after 48 hours, leading to eradication of multifocal cancer lesions. Efficacy data, together with good tolerability results, indicate that AvidinOX is a highly innovative reagent for tissue-pretargeted radionuclide therapy.

Original languageEnglish
Pages (from-to)143-148
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume25
Issue number2
DOIs
Publication statusPublished - Apr 1 2010

Fingerprint

Avidin
Radioisotopes
Biotin
Therapeutics
Schiff Bases
Carboxylic Acids
Aldehydes
Half-Life
Breast
Binding Sites
Carbohydrates
Neoplasms
Proteins

Keywords

  • ™cancer
  • AvidinOX
  • Pretargeting
  • Radionuclide therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Medicine(all)

Cite this

De Santis, R., Leoni, B., Rosi, A., Albertoni, C., Forni, G., Cojoca, R., ... Carminati, P. (2010). AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy. Cancer Biotherapy and Radiopharmaceuticals, 25(2), 143-148. https://doi.org/10.1089/cbr.2009.0738

AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy. / De Santis, Rita; Leoni, Barbara; Rosi, Antonio; Albertoni, Claudio; Forni, Guido; Cojoca, Rodica; Iezzi, Manuela; Musiani, Piero; Paganelli, Giovanni; Chinol, Marco; Carminati, Paolo.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 25, No. 2, 01.04.2010, p. 143-148.

Research output: Contribution to journalArticle

De Santis, R, Leoni, B, Rosi, A, Albertoni, C, Forni, G, Cojoca, R, Iezzi, M, Musiani, P, Paganelli, G, Chinol, M & Carminati, P 2010, 'AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy', Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 2, pp. 143-148. https://doi.org/10.1089/cbr.2009.0738
De Santis, Rita ; Leoni, Barbara ; Rosi, Antonio ; Albertoni, Claudio ; Forni, Guido ; Cojoca, Rodica ; Iezzi, Manuela ; Musiani, Piero ; Paganelli, Giovanni ; Chinol, Marco ; Carminati, Paolo. / AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy. In: Cancer Biotherapy and Radiopharmaceuticals. 2010 ; Vol. 25, No. 2. pp. 143-148.
@article{1f3bce59919048c9b7916aca5ed1f486,
title = "AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy",
abstract = "Avidin is widely used in vitro for its capacity to bind biotin. However, avidińs in vivo use is limited by its short residence in blood and tissues. An avidin variant, named AvidinOX,™ has been recently described. This product is obtained by 4-hydroxyazobenzene-2-carboxylic acid-assisted sodium periodate oxidation of avidin. This method generates aldehyde groups from avidin carbohydrates, sparing biotin-binding sites from inactivation. AvidinOX binds cellular and interstitial protein amino groups through Schiff's bases, resulting in a tissue half-life of 2 weeks, compared with 2 hours of native avidin. Binding of AvidinOX occurs in normal and neoplastic tissues. Data show that AvidinOX, administered intranipple in the breast of transgenic BALB/neuT mice, is highly efficient for capturing 90Y-biotinDOTA, intravenously injected after 48 hours, leading to eradication of multifocal cancer lesions. Efficacy data, together with good tolerability results, indicate that AvidinOX is a highly innovative reagent for tissue-pretargeted radionuclide therapy.",
keywords = "™cancer, AvidinOX, Pretargeting, Radionuclide therapy",
author = "{De Santis}, Rita and Barbara Leoni and Antonio Rosi and Claudio Albertoni and Guido Forni and Rodica Cojoca and Manuela Iezzi and Piero Musiani and Giovanni Paganelli and Marco Chinol and Paolo Carminati",
year = "2010",
month = "4",
day = "1",
doi = "10.1089/cbr.2009.0738",
language = "English",
volume = "25",
pages = "143--148",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - AvidinOX™ for highly efficient tissue-pretargeted radionuclide therapy

AU - De Santis, Rita

AU - Leoni, Barbara

AU - Rosi, Antonio

AU - Albertoni, Claudio

AU - Forni, Guido

AU - Cojoca, Rodica

AU - Iezzi, Manuela

AU - Musiani, Piero

AU - Paganelli, Giovanni

AU - Chinol, Marco

AU - Carminati, Paolo

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Avidin is widely used in vitro for its capacity to bind biotin. However, avidińs in vivo use is limited by its short residence in blood and tissues. An avidin variant, named AvidinOX,™ has been recently described. This product is obtained by 4-hydroxyazobenzene-2-carboxylic acid-assisted sodium periodate oxidation of avidin. This method generates aldehyde groups from avidin carbohydrates, sparing biotin-binding sites from inactivation. AvidinOX binds cellular and interstitial protein amino groups through Schiff's bases, resulting in a tissue half-life of 2 weeks, compared with 2 hours of native avidin. Binding of AvidinOX occurs in normal and neoplastic tissues. Data show that AvidinOX, administered intranipple in the breast of transgenic BALB/neuT mice, is highly efficient for capturing 90Y-biotinDOTA, intravenously injected after 48 hours, leading to eradication of multifocal cancer lesions. Efficacy data, together with good tolerability results, indicate that AvidinOX is a highly innovative reagent for tissue-pretargeted radionuclide therapy.

AB - Avidin is widely used in vitro for its capacity to bind biotin. However, avidińs in vivo use is limited by its short residence in blood and tissues. An avidin variant, named AvidinOX,™ has been recently described. This product is obtained by 4-hydroxyazobenzene-2-carboxylic acid-assisted sodium periodate oxidation of avidin. This method generates aldehyde groups from avidin carbohydrates, sparing biotin-binding sites from inactivation. AvidinOX binds cellular and interstitial protein amino groups through Schiff's bases, resulting in a tissue half-life of 2 weeks, compared with 2 hours of native avidin. Binding of AvidinOX occurs in normal and neoplastic tissues. Data show that AvidinOX, administered intranipple in the breast of transgenic BALB/neuT mice, is highly efficient for capturing 90Y-biotinDOTA, intravenously injected after 48 hours, leading to eradication of multifocal cancer lesions. Efficacy data, together with good tolerability results, indicate that AvidinOX is a highly innovative reagent for tissue-pretargeted radionuclide therapy.

KW - ™cancer

KW - AvidinOX

KW - Pretargeting

KW - Radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=77951944470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951944470&partnerID=8YFLogxK

U2 - 10.1089/cbr.2009.0738

DO - 10.1089/cbr.2009.0738

M3 - Article

C2 - 20423226

AN - SCOPUS:77951944470

VL - 25

SP - 143

EP - 148

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 2

ER -